NCP112

DRUG2 trials

Sponsors

NovaCell Technology Inc., Huons Co., Ltd.

Conditions

Atopic DermatitisXerophthalmia

Phase 1

A Single-center, Randomized, Double-blinded, Placebo-controlled, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of NCP112

CompletedNCT05638165

NovaCell Technology Inc.Atopic Dermatitis

Start: 2021-10-13End: 2021-11-20Updated: 2022-12-19

Clinical Study for the Evaluation of Safety and Tolerability of NCP112 Eye Drops

RecruitingNCT06263998

Huons Co., Ltd.Xerophthalmia

Start: 2024-07-11End: 2026-01-30Target: 60Updated: 2024-10-01